Blood: Clinical benefit of ruxolitinib targeted inhibition of JAK/STAT in patients with T-cell lymphoma

Peripheral T-cell lymphoma (PTCL) and non-mycosis fungoides (non-MF) Cutaneous T-cell lymphoma (CTCL) is a markedly heterogeneous group of diseases characterized by relatively low cure rates with initial therapy , options for relapsed or refractory disease are limited

lymphoma

Signaling through JAK1 and/or JAK2 is common in both tumor and non-tumor cells of peripheral T-cell lymphoma (PTCL)

This study is a phase 2 study of the JAK1/2 inhibitor ruxolitinib in patients with relapsed or refractory PTCL (n=45) or mycosis fungoides (n=7)

Clinical benefit profiles by cohort and subtype

Clinical benefit profiles by cohort and subtype

Only 1 of 7 MF patients had clinical benefit (objective response >18 months)

In cohorts 1, 2, and 3 of PTCL cases (n=45), the CBR rates were 53%, 45%, and 13% leukemia , respectively

Treatment effects of different cohorts of PTCL patients

Treatment effects of different cohorts of PTCL patients

In an exploratory analysis using multiplex immunofluorescence , expression of phosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, in <25% of tumor cells correlated with response to ruxolitinib treatment.

Expression of immunophosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, correlates with responsiveness to ruxolitinib treatment in <25% of tumor cells Phosphorylated S6, a PI3 kinase or markers of mitogen-activated protein kinase activation) expression in <25% of tumor cells correlated with responsiveness to ruxolitinib treatment

In conclusion, this study demonstrates that ruxolitinib has antitumor activity in various PTCL subtypes, suggesting that PTCL patients may be able to employ precision therapeutic strategies for JAK/STAT inhibition

Ruxolitinib has antitumor activity in various PTCL subtypes, suggesting that PTCL patients may be able to adopt precision treatment strategies for JAK/STAT inhibition

Original source:

Alison J.

A phase 2 biomarker-driven study of ruxolitinib demonstrates the effectiveness of JAK/STAT targeting in T-cell lymphomasLeave

a comment here